Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Novartis starts Phase III trials of ligelizumab for urticaria

CSU is a severe, unpredictable skin condition that results in spontaneous swelling of the skin. Credit: diana_rajchel.



  • Novartis

Go Top